Patent strengthens Autonomix's intellectual property position in the nerve-mapping and denervation space, supporting the Company's broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company ...

The University of Florida Veterinary Hospital, a leader in advanced veterinary care and research, is now licensed and equipped to deliver IsoPet therapy as part of its oncology services. This certification expands the availability of a targeted, minimally invasive cancer treatment that uses a proprietary radionuclide injection to treat solid tumors in pets. Kennewick, WA, May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that the University of Florida Veterinary Hospital has been cer ...

MARKHAM, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of May 2025, representing $0.936 per Common Share on an annualized basis. The dividend will be payable on June 13, 2025 to shareholders of record as at May 30, 2025. Sienna Senior Living Inc. (TSX:SIA) offers a full range of senior living options, including independent living, assisted l ...

Wednesday, May 28, 2025 at 10:00 A.M. Shareholders will have the ability to interact with Dorel Industries Inc. Senior Management by submitting questions to ir@dorel.com. To be sure your questions are addressed during the Q&A portion of the annual meeting, please submit them no later than 5 p.m. on Friday, May 23, 2025. MONTREAL, May 15, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) Shareholders are invited to participate by live audio webcast at https://www.dorel.com/pages/shareholder- ...

Management Commentary NEW YORK and TOKYO, May 15, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) ("HeartCore" or the "Company"), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Operational & Financial Highlights HeartCore CEO Sumitaka Kanno commented: "We continued to make meaningful strategic advancements across our software business this quarter, the corne ...

VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) ("Ascot" or the "Company") announces that following the recently announced director resignations, the Company is filing an amended and restated notice of meeting (the "Amended Notice"), form of proxy (the "Amended Proxy") and management information circular (the "Amended Circular" and together with the Amended Notice and the Amended Proxy, the "Amended Meeting Materials") with respect to its annual ge ...

IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Apple iSports Group, Inc. (OTC-QB: AAPI) ("Company" or "Apple iSports"), an entertainment, media, iGaming, and technology services company, is pleased to announce it has signed a non-binding Letter of Intent with AmeriCrew Inc., a Delaware corporation ("AmeriCrew"), a technology infrastructure and managed services company. Key Highlights Strategic and Financial Rationale Key The proposed acquisition shows Apple iSports' ability to follow through on its strate ...

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parent ...

Mr. Knuettel brings more than two decades of executive leadership experience across dynamic, early-stage public companies in the technology and life sciences sectors. He currently serves as Chief Executive Officer of Channel Therapeutics Corporation since 2023, having started as CFO in 2022. Known for his operational discipline and M&A acumen, Mr. Knuettel has helped companies scale aggressively, including spearheading a revenue expansion at Unrivaled Brands from $10 million to $100 million annualized in ju ...

The profile discusses Brag House's: "By merging gameplay with school spirit, and backing it with real-time analytics and scalable monetization tools, we're creating a powerful framework that will enable brands to reach Gen Z with greater precision, authenticity, and ROI," added Malloy. As highlighted in the Company's recent 10-K filing, Brag House is executing a multi-university activation roadmap with Learfield and continuing to invest in platform enhancements, branded experiences, NIL- integrated content, ...